Effect of alirocumab on postprandial hyperlipidaemia in patients with type 2 diabetes: A randomized, double‐blind, placebo‐controlled, cross‐over trial
Inhibition of PCSK9 by alirocumab did not reduce PPL in T2D, confirming that PCSK9 controls remnant cholesterol catabolism rather than intestinal chylomicron production.
Authors
- Bertrand Cariou (ORCID: https://orcid.org/0000-0002-1580-8040)
- Arsênio Rodrigues Oliveira (ORCID: https://orcid.org/0000-0001-9836-9161)
- Béatrice Guyomarch
- Claire Cannet
- Maxime Carpentier
- Pierre Morcel
- Patrick Giraudeau (ORCID: https://orcid.org/0000-0001-9346-9147)
- Mikaël Croyal (ORCID: https://orcid.org/0000-0002-5449-5817)
- Audrey Ernould
- An Thys (ORCID: https://orcid.org/0000-0002-6838-312X)
- Cédric Le May (ORCID: https://orcid.org/0000-0002-7554-792X)
- Laurent Flet (ORCID: https://orcid.org/0000-0001-8305-7085)
- Marine P. M. Letertre (ORCID: https://orcid.org/0000-0002-7777-1001)
- Samy Hadjadj
Institutions
- Centre National de la Recherche Scientifique (FR)
- Inserm (FR)
- Centre Hospitalier Universitaire de Nantes (FR)
- Chimie et Interdisciplinarité, Synthèse, Analyse, Modélisation (FR)
- Bruker (Germany) (DE)
- Institut du Thorax (FR)
- Nantes Université (FR)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2025-03-05
- DOI
- https://doi.org/10.1111/dom.16305
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 0.00